This week in pharma… 14th October

14th October, 2022

In this week’s news, Samsung Biologics has announced Plant 4 has commenced GMP operations: Sharp has strengthened its clinical leadership team and more.

Michael Morgen of Lonza Bend, Torkel Gren of Recipharm, and Yogesh Sadhale of Metrics Contract Services, discuss the current trends and innovations influencing oral drug delivery development and what their respective companies can offer to pharma in this space.

The powder and liquid transfer specialist, ChargePoint Technology Group, and leading provider of infection prevention and other procedural products and services, STERIS, have partnered to provide a successful sterile solution to specialty chemicals company, Evonik.

Samsung Biologics, a South Korea-based contract development and manufacturing organization (CDMO), has announced that its Plant 4, the world’s largest single biomanufacturing plant, has commenced GMP operations this month.

Sharp, a leading provider of pharmaceutical packaging and clinical services, has strengthened its clinical leadership team with a new Director, Analytical and Formulation Services and also a new Vice President, Global Business Development.

The digital therapeutics revolution is happening and Big Pharma is buying in — with caution. Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.

Also in the news

New TYK2 inhibitors: a growing race to top Bristol Myers. The pharmaceutical company’s psoriasis drug Sotyktu was the first of its kind to win approval. A group of well-funded startups think they can do better.

CDMO trends

InstantGMP, the originators of the all-in-one manufacturing and quality system, is proud to welcome CDMO, Quality Chemical Laboratories (QCL), to its growing client base. 

CDMO Fujifilm Diosynth Corporation will receive up to $185 million after Novavax cancelled a Commercial Supply Agreement (CSA) relating to its COVID-19 vaccine. According to an SEC filing, the CSA dated August 20, 2021, and a Master Services Agreement (MSA) dated June 30, 2020, between Novavax and Fujifilm have been terminated. 

Development and Manufacturing Organization (CDMO) Outsourcing Market report 2022 gives in-depth information about Players Profiles, Basic Information, Manufacturing Base, Sales Area, and Competitors which include manufacturers like Recipharm AB, FAREVA SA, Lonza, Lubrizol Corporation, BioXcellence, Patheon, Thermo Fisher Scientific Inc, Aenova Holding GmbH, FAMAR, WuXi Biologics, Catalent Inc, Almac Group Ltd, and Siegfried Holding AG.